
    
      A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group
      Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral
      Neurokinin-1 Receptor Antagonist, GW67969, When Administered With Intravenous Ondansetron
      Hydrochloride for the Prevention of Post-Operative Nausea and Vomiting (PONV) and
      Post-Discharge Nausea and Vomiting (PDNV) in Female Subjects With Known Risk Factors for PONV
      Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk
    
  